Abstract
Anemia is the most common extraintestinal complication of inflammatory bowel disease (IBD), with approximately half of cases caused by iron deficiency (ID). Intravenous (IV) iron is the preferred ID anemia (IDA) treatment where oral iron is contraindicated, ineffective or not tolerated, or where correction of ID is urgent. The recent PHOSPHARE-IBD randomized controlled trial (RCT; ClinialTrials.gov ID NCT03466983) reported significantly higher incidence of hypophosphatemia after treatment with ferric carboxymaltose (FCM) than ferric derisomaltose (FDI). The present study objective was to evaluate the cost-utility of FDI versus FCM in patients with IBD in Italy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
